Axovant Sciences (NYSE: AXON), a leading clinical-stage biopharmaceutical company focused on the treatment of dementia, entered into a $55.0 million debt financing agreement with Hercules Capital, Inc. (NYSE: HTGC) ("Hercules"), a leader in customized debt financing for companies in life sciences and technology-related markets.
VISCHER advises Axovant in this financing in Swiss law matters, the team consists of Dr. Adrian Dörig (Partner, Corporate), Christoph Niederer (Partner, Tax), Dania Salvisberg (Senior Associate, Corporate) and Ruben Masar (Associate, Corporate).